Navigation Links
Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
Date:11/20/2007

CRANBURY, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Lazard Capital Markets Fourth Annual Healthcare Conference in New York City on Tuesday, November 27th at 11:30 am ET at The New York Palace Hotel.

A live audio web cast of the presentation will be available to all interested parties through the Investors section of Amicus' website at http://www.amicustherapeutics.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company announced positive data from Phase I clinical trials of AT2220 for the treatment of Pompe disease in October 2007.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forw
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... 25, 2012 Aviir Diagnostic Laboratory announced today ... with MultiPlan, Inc. for ancillary diagnostics laboratory testing. ... PHCS and PHCS Savility Networks. Aviir ... from the Stanford University School of Medicine to ...
... The rise of the corporate venture fund and the ... themes at BioTrinity, the-premier European biopartnering and investment conference ... comprehensive support for bioscience businesses in the Oxford and ... day of the conference saw senior figures from Merck ...
... well-respected, independent, third-party laboratory has tested for Tuberculosis (TB) ... (BioNanoPore) test kits and achieved the detection of ... culture times for conventional technologies take a minimum of ... concurrent tests for TB at the same facility, using ...
Cached Biology Technology:Aviir Laboratories Announce National Agreement With MultiPlan 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 3NanoLogix Provides Testing and Operations Update 2NanoLogix Provides Testing and Operations Update 3
(Date:5/23/2013)... Neuron , the team reveal the interplay of brain ... by the Wellcome Trust and BBSRC. , By ... improve our perceptual abilities. While these changes can affect ... affect the fidelity of that response. , ... "When you communicate with others, you can make yourself ...
(Date:5/22/2013)... that can detect molecular variants in chemical mixtures ... most important, though time-consuming, processes in analytical chemistry. ... , post-doctoral researcher David Patterson, Professor of Physics John ... Free-Electron Laser Science (CFEL) in Hamburg, Germany developed a ... molecular variants apart, and to determine how much variant ...
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3DNA damage: The dark side of respiration 2
... PHILADELPHIA A new study by University of Pennsylvania ... humans, that ventilators combined with diaphragm disuse contributes to ... eighteen hours. Muscle atrophy in the diaphragm is a ... mechanical ventilation often have difficulty breathing after being removed ...
... German . , The "Large Molecule Heimat" ... forming region Sagittarius B2. In this source of only 0,3 ... formed star, most of the interstellar molecules known to date ... ethyl alcohol, formaldehyde, formic acid, acetic acid, glycol aldehyde (a ...
... Humans have regularly been introducing exotic species into ... nutritional necessities or meet less indispensable purposes such ... environments are not always adapted for hosting new ... wild rabbit into Australia or brown fario trout ...
Cached Biology News:Long-term use of mechanical ventilation contributes to the deterioration of human diaphragm muscle 2New organic molecule in space 2Conservation of freshwater fish biodiversity: a challenge for the countries of the South 2Conservation of freshwater fish biodiversity: a challenge for the countries of the South 3
... optically clear polystyrene formulation , High antibody-binding ... , Plates are certified for performance ... , Eight-well strips fit snugly in ... in use even if turned upside down ...
...
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
... StabilGuard Biomolecule Stabilizer is a bovine protein-free ... is an aqueous solution that contains non-toxic ... saline), pH 6.6 - 7.2, and does ... maintains the activity of antibodies and other ...
Biology Products: